The first case of COVID-19 treated with the complement C3 inhibitor AMY-101
S Mastaglio, A Ruggeri, AM Risitano, P Angelillo… - Clinical …, 2020 - Elsevier
Acute respiratory distress syndrome (ARDS) is a devastating clinical manifestation of COVID-
19 pneumonia and is mainly based on an immune-driven pathology. Mounting evidence
suggests that COVID-19 is fueled by a maladaptive host inflammatory response that involves
excessive activation of innate immune pathways. While a “cytokine storm” involving IL-6 and
other cytokines has been documented, complement C3 activation has been implicated as an
initial effector mechanism that exacerbates lung injury in preclinical models of SARS-CoV …
19 pneumonia and is mainly based on an immune-driven pathology. Mounting evidence
suggests that COVID-19 is fueled by a maladaptive host inflammatory response that involves
excessive activation of innate immune pathways. While a “cytokine storm” involving IL-6 and
other cytokines has been documented, complement C3 activation has been implicated as an
initial effector mechanism that exacerbates lung injury in preclinical models of SARS-CoV …